Perrigo Rogaine Foam ANDA May Help Extend Record Growth
This article was originally published in The Tan Sheet
Executive SummaryPerrigo's regulatory green light to market the first OTC generic of Men's Rogaine Foam further extends the pipeline that has kept the firm on a streak of record earnings.
You may also be interested in...
Perrigo debuts Rogaine Foam equivalent; Pfizer patent suit applies heat to J&J/McNeil; Merck KGaA consumer unit beats forecast; Abbott seeks expanded vitamin D3 use; Hi-Tech Pharmacal adds to homeopathics portfolio; more news In Brief.